Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in CMV-seronegative recipients of CMV-seropositive donor kidneys Post hoc analysis of a randomized, phase 3 trial of letermovir versus valganciclovir prophylaxis. (PubMed, Am J Transplant) - Jul 24, 2025 - P3 | "Adult CMV D+R- KTRs were randomized (1:1) post-transplant to letermovir 480 mg (with acyclovir and valganciclovir placebo) or valganciclovir 900 mg (with acyclovir and letermovir placebos) daily for 28-weeks (NCT03443869). In CMV D+R- KTRs, letermovir prophylaxis was associated with less CMV DNAemia compared to valganciclovir in participants with low kidney function during the 200-day prophylaxis period. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov: NCT03443869, EudraCT: 2017-001055-30."
Journal • P3 data • Retrospective data • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
Barbara Haber; Catherine B Small; Christopher L Gilbert; Klemens Budde; Marta Crespo; Nassim Kamar; Natalya Broyde; Nicole Stauffer; Pamela Moise
|